Carcinoma, Renal Cell  >>  Rencarex (girentuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
NCT02002312: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Completed
2
14
Europe
Lu-177-DOTA-girentuximab, Lu-177-DOTA-cG250
Radboud University Medical Center
Metastatic Clear Cell Renal Cell Carcinoma
06/15
06/15

Download Options